| Market Capitalization (Millions $) |
98 |
| Shares
Outstanding (Millions) |
48 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-5 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
The company is a clinical-stage biotechnology firm focused on discovering, developing, and commercializing therapies for rare pediatric lysosomal storage diseases (LSDs). Its approach includes small molecule therapies, combination therapies, and gene therapy. The lead candidate, PLX-200, is in Phase 2 trials targeting multiple LSDs, including neuronal ceroid lipofuscinoses, Krabbe disease, and Sandhoff disease. Additional drug candidates in development include PLX-300, PLX-100, and PLX-400, which aim to address the underlying causes of these rare diseases.
Company Address: South Tower Paramus 7652 NJ
Company Phone Number: 940-7236 Stock Exchange / Ticker: NASDAQ PLYX
|
